Identification and Management of OOT and OOS Results - Online Training Recording

Course No. 20159A

header-image

Speakers

Dr. Joachim Ermer

Dr. Joachim Ermer

Ermer Quality Consulting

Objectives

Out-of-specification (OOS) test results and their appropriate management is an important topic in pharmaceutical Quality Control and inevitably in the focus of any inspection and audit. The purpose of the seminar is providing an overview on regulatory expectations, which are mainly based on the FDA Guidance for Industry “Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production”, as well as practical recommendations for a GMP-conform investigation.

Background

Although the FDA-Guidance on OOS-results provides detailed instructions how to manage results outside specification, observations and deficiencies dealing with OOS results is still a major issue in inspections, FDA 483s and Warning Letters.

In the speaker’s experience, an important aspect is to establish a clear terminology to facilitate understanding of the investigation phases and the appropriate testing approaches.

Of course, “prevention is better than cure”. For this purpose, it is important to avoid OOS-results, for example by means of a suitable identification of atypical or out-of-trend (OOT) results. The participants will learn how to identify OOT-results and how to establish suitable OOT-limits

Target Group

This Online Training Recording is aimed at executives and employees from quality control, quality assurance, production, regulatory and audit functions who want to gain a better understanding of the GMP requirements for the management of OOS-results and how to establish OOT-limits to better prevent OOS-results.

Technical Details:

To participate in an on demand training course or webinar, you do not need any software. The recordings are made available via a streaming server. In general, the recording is provided in MP4 format, which any PC (Microsoft Windows, Apple IOS) or tablet can easily display.

Timing and Duration:
When you register for the on demand Training course or webinar you can decide at what date you want to follow the training course online. For a 1-day training course you will have 2 days in which the stream is available (for 2-day training course 3 days and for a 3-day training course 4 days). Within in this timeframe you can start & stop the stream according to your needs.
In time before the scheduled date (your desired date) you will receive an e-mail from us with a link for direct participation as well as your log-in data.

Please be aware: The recording does not include the Q & A sessions.

Training Course Documentation and Certificate:
The presentations will be made available as PDF files via download shortly before the online training course.  After the event, you will automatically receive your certificate of participation.

Programme

Definition of OOT and OOS Results
  •  Regulatory “out-of” definitions
    •  atypical, suspect, out-of-trend, out-of-expectation, out-of-specification
  •  Reportable value
  •  Error types (random, systematic)
    •  How can they be distinguished?
  •  Normal or abnormal?
    •  (Normal) distribution of data
Establishing OOT Limits for Release Testing
  •  Statistical approaches
  •  Empirical approaches
  •  Control charts
Establishing OOT Limits for Stability Testing
  •  Impact of OOT results in stability studies (ICH studies, ongoing stability)
  •  Introducing a second dimension (“normal” stability trend)
  •  Statistical approaches
    •  95% prediction interval of the linear regression
    •  Regression control chart
    •  Time-point method
Management of OOT and OOS Results in the Quality Control Laboratory
  •  FDA Guidance and European requirements (EU GMP Guide, MHRA, PIC/S)
  •  Importance of a clear terminology (reportable value, re-analysis, retest, re-sampling)
  •  Investigation pathway: OOS identification & decisions
  •  Phase I: Initial laboratory investigation
  •  Phase II: Full scale investigation           
    •  Phase IIA: Review in production
    •  Phase IIB: Additional laboratory testing (retests, averaging)
  •  Variability and OOS
  •  Reporting and documentation
  •  Appropriate response to OOS observations in inspections
 
Recording from 27 September 2022
Duration of Recording: 2h 56min

ECA-Member*: € 590,-
Regular Fee*: € 690,-
APIC Member Discount*: € 640,-

(All prices excl. VAT). Important notes on sales tax.

* also payable by credit card
American Express Visa Mastercard

icon
Further dates on-site
Further dates on-site
Not available
icon
Further dates online
Further dates online
Not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0
E-Mail: info@gmp-compliance.org

Woman with headset

Go back

Testimonials about our courses and conferences

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023

 

“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024

 

“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024

 

 

“Well prepared presentations and good presenters. I also like the way of asking questions.”

Alexandra Weidler, Hookipa Biotech GmbH, Austria
Live Online Training – QP Education Course Module A, November 2023